Traditional Chinese medicine composition for treating myelodysplastic syndrome and applications thereof

Abstract

The invention provides a traditional Chinese medicine composition for treating myelodysplastic syndrome and applications thereof. The traditional Chinese medicine is composed of the following raw materials in parts by weight: 10 to 50 parts of lygodium japonicum, 10 to 50 parts of eucommia leaf, and 40 to 90 parts of oldenlandia diffusa. A new drug for treating myelodysplastic syndrome is added into the drug list, the drug choosing range for patients is enlarged, and a new candidate drug is developed for treating myelodysplastic syndrome.

Description

(1) Technical field [0001] The invention relates to a traditional Chinese medicine composition for treating myelodysplastic syndrome and its application. (2) Background technology [0002] Myelodysplastic syndromes (myelodysplastic syndromes, MDS) are a group of malignant clonal stem cell diseases characterized by ineffective hematopoiesis in the bone marrow and reduction of one, two or multiple lines of peripheral blood cells, and have a high risk of transformation to acute leukemia. The rate is as high as 3.3 / 100,000 (Cogle C.R., Craig B.M., Rollison D.E., et al. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries[J]. Blood, 2011, 117 (26):7121-5.). At present, newly diagnosed high-risk MDS has an upward trend (Sekeres M.A., Schoonen W.M., Kantarjian H., et al.Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys[J].J Natl Cancer Inst...

AI Technical Summary

Problems solved by technology

Among them, the low-risk group is treated with cytokine combined supportive therapy, and the focus of treatment is to improve hematological abnormalities. The middle-risk group and high-risk group often have multilineage hematopoiesis and malignant clonal hyperplasia at the same time. The goal of treatment is to reduce the risk of leukemia transformation. To improve the prognosis, the treatment is mainly chemotherapy combined with cytokine therapy, the curative effect is worse than that of acute myeloid leukemia (AML). Allogeneic hematopoietic stem cell transplantation can have a better effect, but the risk related to transplantation is significantly higher than that of leukemia ( Greenberg P.L..Current therapeutic approaches for patients with myelodysplastic syndromes.Br J Haematol,2010,150(2):131-43.Estey E..Acutemyeloid leukemia and myelodysplastic syndromes in older patients.J Clin Oncol,2007,25:1 15. Estey E.H., Thall P.F., Cortes J.E., et al. Comparison of idarubicin+ara-C-, fludarabine+ara-C-, and topotecan+ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood, 2001, 98(13):3575-83.)

However, since most patients are elderly and cannot tolerate bone marrow transplantation, and the risks associated with transplantation are high, most patients have to rely on drug treatment and blood transfusion to survive, and eventually transform into AML and die. Primary AML is an abnormality in the bone marrow. Blast cells (leukemic cells) proliferate in large numbers and infiltrate various organs and tissues, so that normal hematopoiesis is inhibited. The remission rate of conventional chemotherapy is 55-72%. The characteristics are very different, insensitive to chemotherapy, prone to drug resistance, and poor prognosis

In recent years, the demethylation drugs 5-aza-cytidine (5-aza-cytidine, Aza C) and 5-aza-2'-deoxycytidine (5-aza- 2'-deoxycitidine, DAC), due to non-targeted cytotoxicity, potential carcinogenicity, emergence of drug-resistant cases after clinical application, and expensive treatment costs, limit its therapeutic application in MDS (Qin T., Castoro R ., EI Ahdab S., et al.Mechanisms of resistance to decitabine in the myelodysplastic syndrome.PLoS One, 2011, 6(8):e23372)

Images